title: Bilateral facial nerve palsy in the course of neuroborreliosis in children-dynamics, laboratory tests and treatment.
abstract: OBJECTIVE
  Presentation of four patients with bilateral peripheral facial nerve palsy as a clinical manifestation of neuroborreliosis in children--diagnostic, treatment and prognosis.
  
  
  METHODS
  In 2002-2004 in The Chair and Department of Developmental Neurology, 24 children from the Wielkopolska region were admitted with diagnosis of borreliosis. Among all the children with borreliosis, confirmed by serologic examination, 4 (16.7%) demonstrated bilateral peripheral facial palsy (PFP). We investigated the presence of IgM class and IgG class specific antibodies in the sera and cerebrospinal fluid (CSF) of 4 patients with bilateral PFP. (Detected by immunoenzymatic methods--ELISA.)
  
  
  RESULTS
  Before the occurrence of PFP all the children manifested unspecified systemic symptoms such as headaches, muscle and articulation pains, weakness and in two cases a mood depression. At first all patients demonstrated elevated IgM antibodies and proper levels of IgG antibodies. Control tests administered within 2-14 months later reduction of antibodies was indicated. Two patients demonstrated significant pleocytosis in CSF test, (without the meningeal symptoms). All children were treated with physiotherapeutic procedures and were administered antibiotic intravenously.
  
  
  CONCLUSIONS
  PFP is one of the most frequent neurological symptoms of borreliosis in children. In case of acute PFP and especially the bilateral form of PFP, neuroborreliosis is the most probable diagnosis. All children reported PFP at one side first and after several weeks the paresis of the facial nerve on the opposite side usually appeared. The clinical state of children started to improve after the introduction of physiotherapy and this process usually lasted several months.
authors.affiliation: Chair and Department of Developmental Neurology Poznań University of Medical Sciences, Poland. albrecht@amp.edu.pl
authors.forename: J
authors.initials: J
authors.lastname: Młodzikowska-Albrecht
authors.forename: M
authors.initials: M
authors.lastname: Zarowski
authors.forename: B
authors.initials: B
authors.lastname: Steinborn
authors.forename: A
authors.initials: A
authors.lastname: Winczewska-Wiktor
authors.forename: B
authors.initials: B
authors.lastname: Gurda
authors.forename: J
authors.initials: J
authors.lastname: Wigowska-Sowińska
mesh_terms: D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001898:Borrelia / Q000302:isolation & purification*; D002648:Child; D004599:Electric Stimulation Therapy; D005155:Facial Nerve Diseases / Q000382:microbiology / Q000628:therapy*; D005158:Facial Paralysis / Q000382:microbiology / Q000628:therapy*; D005260:Female; D006801:Humans; D020852:Lyme Neuroborreliosis / Q000150:complications / Q000175:diagnosis* / Q000628:therapy*; D008297:Male; D012698:Serologic Tests; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents